Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Natural house dust mite allergen extract is a biologic product used in allergen immunotherapy (AIT) for the treatment of house dust mite-induced allergic diseases, including allergic asthma and allergic rhinitis. The extract is typically derived from the house dust mite species *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*, containing a complex mixture of major and minor allergens such as Der p 1, Der p 2, Der f 1, and Der f 2. It is often formulated as a semi-depot preparation (adsorbed to aluminum hydroxide) for subcutaneous injection (SCIT). The mechanism of action involves inducing immunological tolerance by modulating the immune system's response to these allergens, shifting from a Th2-biased allergic profile to a Th1-biased or regulatory T cell (Treg) profile, and increasing the production of allergen-specific IgG4 blocking antibodies. Clinical trials, such as ChiCTR2500100575, evaluate accelerated up-dosing regimens to reach maintenance doses more efficiently in pediatric populations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on natural house dust mite allergen extract.